quadrivalent influenza mRNA vaccine (CVSQIV)
/ CureVac, GSK
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 06, 2023
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults
(clinicaltrials.gov)
- P1 | N=240 | Completed | Sponsor: CureVac | Recruiting ➔ Completed
Trial completion • Infectious Disease • Influenza • Respiratory Diseases
1 to 1
Of
1
Go to page
1